GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$19.39
-0.42 (-2.12%)
Open$19.66
Previous Close$19.81
Day High$20.11
Day Low$19.16
52W High$25.77
52W Low$3.51
Volume—
Avg Volume691.3K
Market Cap1.59B
P/E Ratio—
EPS$-0.45
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+98.3% upside
Current
$19.39
$19.39
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 121.70M | 401.98M | 400.93M |
| Net Income | -38,013,215 | -29,192,444 | -34,329,564 |
| Profit Margin | -31.2% | -7.3% | -8.6% |
| EBITDA | -45,068,140 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |